Hep B cAg Antibody (14-E-11): sc-52409

Hep B cAg Antibody (14-E-11) is a mouse monoclonal IgG2a antibody that detects Hep B cAg protein of Hepatitis B by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Hep B cAg, or Hepatitis B core antigen, plays a crucial role in the life cycle of the Hepatitis B virus, as Hep B cAg forms the protein shell, or capsid, that encases the viral genome. Hep B cAg is essential for the assembly and stability of the virus, allowing viral replication and host cell infection. The presence of Hep B cAg in the serum is a key indicator of active viral replication and infection, making Hep B cAg a vital target for diagnostic assays. Understanding Hep B cAg dynamics is important not only for diagnosing Hepatitis B but also for monitoring the effectiveness of antiviral therapies. Hep B cAg is primarily expressed in the liver, where the virus exerts pathogenic effects, leading to liver inflammation and potential long-term complications such as cirrhosis and hepatocellular carcinoma. Hep B cAg Antibody (14-E-11) is therefore an invaluable tool for researchers and clinicians working to unravel the complexities of Hepatitis B infection and associated health risks.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Hep B cAg Antibody (14-E-11) References:

1. Interactions of hepatitis B core antigen and peptide inhibitors.  |  Tang, KF., et al. 2007. J Med Chem. 50: 5620-6. PMID: 17918821
2. Antibody to hepatitis B core antigen in patients with hepatocellular carcinoma.  |  Kubo, Y., et al. 1977. Gastroenterology. 72: 1217-20. PMID: 192626
3. The novel use of a routine quantitative system to analyze the activity, content and affinity of an antibody to hepatitis B core antigen.  |  Han, Y., et al. 2011. J Clin Virol. 52: 295-9. PMID: 21978612
4. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.  |  Li, J., et al. 2015. Vaccine. 33: 4247-54. PMID: 25858855
5. Associations between antibody to hepatitis B core antigen positivity and outcomes in hepatocellular carcinoma patients undergoing hepatic resection.  |  Itoh, S., et al. 2018. Hepatol Res. 48: E155-E161. PMID: 28710825
6. Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.  |  Chen, Z., et al. 2018. Proc Natl Acad Sci U S A. 115: E11369-E11378. PMID: 30420516
7. An enzyme-immunoassay for antibodies against hepatitis B core antigen: characteristics and clinical validation.  |  Matthyssen, L., et al. 1987. J Virol Methods. 17: 95-103. PMID: 3312270
8. Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level in vivo is dependent on de novo core protein translation.  |  Berke, JM., et al. 2024. J Virol. 98: e0150223. PMID: 38315015
9. Significance of antibody to hepatitis B core antigen in a hemodialysis unit.  |  Wasnich, RD., et al. 1980. West J Med. 132: 279-82. PMID: 7385831
10. Microencapsulation of hepatitis B core antigen for vaccine preparation.  |  Uchida, T., et al. 1998. Pharm Res. 15: 1708-13. PMID: 9833992

The preferred Hep B cAg antibody is Hep B cAg Antibody (C1-5): sc-23945.